BRIEF: Shandong Gold profit surges in first half of 2025

1787.HK 600547.SHG
Jiumaojiu is a consumer brand

Gold producer Shandong Gold Mining Co. Ltd. (1787.HK; 600547.SH) announced on Monday that it expects to report an interim net profit of 2.55 billion yuan ($356 million) to 3.05 billion yuan for the first half of 2025, up 84.3% to 120.5% compared to the same period in 2024.

The company also forecasts its net profit attributable to shareholders, excluding non-recurring gains and losses, to reach 2.55 billion yuan to 3.05 billion yuan, up 80.3% to 115.6% year-on-year.

Shandong Gold attributed the strong performance to more efficient production planning, refined management, and improvements in its operational efficiency and resource utilization. Higher gold prices also significantly boosted its profitability.

Shandong Gold’s shares opened flat on Tuesday, and closed at HK$26.50, down 1.6% by the midday break. The stock is up 36% so far this year.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

,
,

Related Articles

RELATED ARTICLES

  1. Zijin Mining spinning off its overseas gold mining arm and taking it public, in order to benefit from surging gold price
    Zijin Mining sees gold in IPO for international arm
    2899.HK 601899.SHG
  2. High gold prices may take the shine off Hipine as it seeks Hong Kong IPO
  3. BRIEF: Shandong Gold logs strong first-quarter profit growth
    1787.HK
  4. Chow Tai Fook rediscovers gold in convertible bonds
    1929.HK
  5. BitFuFu rides crypto wave, flexible business model to lofty profits
    FUFU.US
  6. Cango takes ‘Mine and Hold’ strategy in its young bitcoin business
    CANG.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Kelun-Biotech reported rising sales of its signature cancer drug

Precision cancer drugs show promise for Kelun-Biotech

The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
6990.HK
Illustration of China's hydrogen battery industry

China plays defense on EV batteries, offense on hydrogen

China rolls out new rules restricting the export of cutting-edge technology for EV battery manufacturing. How will this affect Chinese battery makers setting up factories abroad? And hydrogen fuel cell maker Refire reports its revenue fell 10% in the first half of the year. What does this say about a Chinese sector that's getting huge government support, but has yet to find a mass audience?
3750.HK 2570.HK